Tau imaging using PET is a promising tool for the diagnosis and evaluation of tau-related neurodegenerative disorders, but the relationship among PET-detectable tau, neuroinflammation, and neurodegeneration is not yet fully understood.
Objective:
We aimed to elucidate sequential changes in tau accumulation, neuroinflammation, and brain atrophy by PET and MRI in a tauopathy mouse model.
Methods:
rTg4510 transgenic (tg) mice expressing P301L mutated tau and non-tg mice were examined with brain MRI and PET imaging (analyzed numbers: tg = 17, non-tg = 13; age 2.5∼14 months). As PET probes, [11C]PBB3 (Pyridinyl-Butadienyl-Benzothiazole 3) and [11C]AC-5216 were used to visualize tau pathology and 18-kDa translocator protein (TSPO) neuroinflammation. Tau pathology and microglia activation were subsequently analyzed by histochemistry.
Results:
PET studies revealed age-dependent increases in [11C]PBB3 and [11C]AC-5216 signals, which were correlated with age-dependent volume reduction in the forebrain on MRI. However, the increase in [11C]PBB3 signals reached a plateau at age 7 months, and therefore its significant correlation with [11C]AC-5216 disappeared after age 7 months. In contrast, [11C]AC-5216 showed a strong correlation with both age and volume reduction until age 14 months. Histochemical analyses confirmed the relevance of pathological tau accumulation and elevated TSPO immunoreactivity in putative microglia.
Conclusion:
Our results showed that tau accumulation is associated with neuroinflammation and brain atrophy in a tauopathy mouse model. The time-course of the [11C]PBB3- and TSPO-PET finding suggests that tau deposition triggers progressive neuroinflammation, and the sequential changes can be evaluated in vivo in mouse brains.
LeeVM, GoedertM, TrojanowskiJQ (2001) Neurodegenerative tauopathies. Annu Rev Neurosci24, 1121–1159.
2.
MaruyamaM, ShimadaH, SuharaT, ShinotohH, JiB, MaedaJ, ZhangMR, TrojanowskiJQ, LeeVM, OnoM, MasamotoK, TakanoH, SaharaN, IwataN, OkamuraN, FurumotoS, KudoY, ChangQ, SaidoTC, TakashimaA, LewisJ, JangMK, AokiI, ItoH, HiguchiM (2013) Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron79, 1094–1108.
3.
HaradaR, OkamuraN, FurumotoS, TagoT, MaruyamaM, HiguchiM, YoshikawaT, AraiH, IwataR, KudoY, YanaiK (2013) Comparison of the binding characteristics of [18F]THK-523 and other amyloid imaging tracers to Alzheimer’s disease pathology. Eur J Nucl Med Mol Imaging40, 125–132.
4.
OkamuraN, FurumotoS, HaradaR, TagoT, YoshikawaT, Fodero-TavolettiM, MulliganRS, VillemagneVL, AkatsuH, YamamotoT, AraiH, IwataR, YanaiK, KudoY (2013) Novel 18F-labeled arylquinoline derivatives for noninvasive imaging of tau pathology in Alzheimer disease. J Nucl Med54, 1420–1427.
5.
ChienDT, BahriS, SzardeningsAK, WalshJC, MuF, SuMY, ShankleWR, ElizarovA, KolbHC (2013) Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. J Alzheimers Dis34, 457–468.
6.
ArizaM, KolbHC, MoecharsD, RomboutsF, AndresJI (2015) Tau positron emission tomography (PET) imaging: Past, present, and future. J Med Chem58, 4365–4382.
7.
VillemagneVL, Fodero-TavolettiMT, MastersCL, RoweCC (2015) Tau imaging: Early progress and future directions. Lancet Neurol14, 114–124.
8.
Saint-AubertL, LemoineL, ChiotisK, LeuzyA, Rodriguez-VieitezE, NordbergA (2017) Tau PET imaging: Present and future directions. Mol Neurodegener12, 19.
9.
OnoM, SaharaN, KumataK, JiB, NiR, KogaS, DicksonDW, TrojanowskiJQ, LeeVM, YoshidaM, HozumiI, YoshiyamaY, van SwietenJC, NordbergA, SuharaT, ZhangMR, HiguchiM (2017) Distinct binding of PET ligands PBB3 and AV-1451 to tau fibril strains in neurodegenerative tauopathies. Brain140, 764–780.
10.
SantacruzK, LewisJ, SpiresT, PaulsonJ, KotilinekL, IngelssonM, GuimaraesA, DeTureM, RamsdenM, McGowanE, ForsterC, YueM, OrneJ, JanusC, MariashA, KuskowskiM, HymanB, HuttonM, AsheKH (2005) Tau suppression in a neurodegenerative mouse model improves memory function. Science309, 476–481.
11.
HuttonM, LendonCL, RizzuP, BakerM, FroelichS, HouldenH, Pickering-BrownS, ChakravertyS, IsaacsA, GroverA, HackettJ, AdamsonJ, LincolnS, DicksonD, DaviesP, PetersenRC, StevensM, de GraaffE, WautersE, van BarenJ, HillebrandM, JoosseM, KwonJM, NowotnyP, CheLK, NortonJ, MorrisJC, ReedLA, TrojanowskiJ, BasunH, LannfeltL, NeystatM, FahnS, DarkF, TannenbergT, DoddPR, HaywardN, KwokJB, SchofieldPR, AndreadisA, SnowdenJ, CraufurdD, NearyD, OwenF, OostraBA, HardyJ, GoateA, van SwietenJ, MannD, LynchT, HeutinkP (1998) Association of missense and 5’-splice-site mutations in tau with the inherited dementia FTDP-17. Nature393, 702–705.
12.
BergerZ, RoderH, HannaA, CarlsonA, RangachariV, YueM, WszolekZ, AsheK, KnightJ, DicksonD, AndorferC, RosenberryTL, LewisJ, HuttonM, JanusC (2007) Accumulation of pathological tau species and memory loss in a conditional model of tauopathy. J Neurosci27, 3650–3662.
13.
KopeikinaKJ, PolydoroM, TaiHC, YaegerE, CarlsonGA, PitstickR, HymanBT, Spires-JonesTL (2013) Synaptic alterations in therTg4510 mouse model of tauopathy. J Comp Neurol521, 1334–1353.
14.
BartenDM, FanaraP, AndorferC, HoqueN, WongPY, HustedKH, CadelinaGW, DecarrLB, YangL, LiuV, FesslerC, ProtassioJ, RiffT, TurnerH, JanusCG, SankaranarayananS, PolsonC, MeredithJE, GrayG, HannaA, OlsonRE, KimSH, ViteGD, LeeFY, AlbrightCF (2012) Hyperdynamic microtubules, cognitive deficits, and pathology are improved in tau transgenic mice with low doses of the microtubule-stabilizing agent BMS-241027. J Neurosci32, 7137–7145.
15.
SaharaN, DeTureM, RenY, EbrahimAS, KangD, KnightJ, VolbrachtC, PedersenJT, DicksonDW, YenSH, LewisJ (2013) Characteristics of TBS-extractable hyperphosphorylated tau species: Aggregation intermediates in rTg4510 mouse brain. J Alzheimers Dis33, 249–263.
16.
RamsdenM, KotilinekL, ForsterC, PaulsonJ, McGowanE, SantaCruzK, GuimaraesA, YueM, LewisJ, CarlsonG, HuttonM, AsheKH (2005) Age-dependent neurofibrillary tangle formation, neuron loss, and memory impairment in a mouse model of human tauopathy (P301L). J Neurosci25, 10637–10647.
17.
DickeyC, KraftC, JinwalU, KorenJ, JohnsonA, AndersonL, LebsonL, LeeD, DicksonD, de SilvaR, BinderLI, MorganD, LewisJ (2009) Aging analysis reveals slowed tau turnover and enhanced stress response in a mouse model of tauopathy. Am J Pathol174, 228–238.
18.
FontaineSN, IngramA, CloydRA, MeierSE, MillerE, LyonsD, NationGK, MechasE, WeissB, LanzillottaC, Di DomenicoF, SchmittF, PowellDK, VandsburgerM, AbisambraJF (2017) Identification of changes in neuronal function as a consequence of aging and tauopathic neurodegeneration using a novel and sensitive magnetic resonance imaging approach. Neurobiol Aging56, 78–86.
19.
MajidT, AliYO, VenkitaramaniDV, JangMK, LuHC, PautlerRG (2014) In vivo axonal transport deficits in a mouse model of fronto-temporal dementia. Neuroimage Clin4, 711–717.
20.
PerezPD, HallG, KimuraT, RenY, BaileyRM, LewisJ, FeboM, SaharaN (2013) In vivo functional brain mapping in a conditional mouse model of human tauopathy (taup301l) reveals reduced neural activity in memory formation structures. Mol Neurodegener8, 9.
21.
Fodero-TavolettiMT, OkamuraN, FurumotoS, MulliganRS, ConnorAR, McLeanCA, CaoD, RigopoulosA, CartwrightGA, O’KeefeG, GongS, AdlardPA, BarnhamKJ, RoweCC, MastersCL, KudoY, CappaiR, YanaiK, VillemagneVL (2011) 18F-THK523: A novel in vivo tau imaging ligand for Alzheimer’s disease. Brain134, 1089–1100.
22.
HolmesHE, ColganN, IsmailO, MaD, PowellNM, O’CallaghanJM, HarrisonIF, JohnsonRA, MurrayTK, AhmedZ, HeggenesM, FisherA, CardosoMJ, ModatM, Walker-SamuelS, FisherEM, OurselinS, O’NeillMJ, WellsJA, CollinsEC, LythgoeMF (2016) Imaging the accumulation and suppression of tau pathology using multiparametric MRI. Neurobiol Aging39, 184–194.
23.
GerhardA, WattsJ, Trender-GerhardI, TurkheimerF, BanatiRB, BhatiaK, BrooksDJ (2004) In vivo imaging of microglial activation with [11C](R)-PK11195 PET in corticobasal degeneration. Mov Disord19, 1221–1226.
24.
GerhardA, Trender-GerhardI, TurkheimerF, QuinnNP, BhatiaKP, BrooksDJ (2006) In vivo imaging of microglial activation with [11C](R)-PK11195 PET in progressive supranuclear palsy. Mov Disord21, 89–93.
25.
Wyss-CorayT (2006) Inflammation in Alzheimer disease: Driving force, bystander or beneficial response?Nat Med12, 1005–1015.
26.
YoshiyamaY, HiguchiM, ZhangB, HuangSM, IwataN, SaidoTC, MaedaJ, SuharaT, TrojanowskiJQ, LeeVM (2007) Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron53, 337–351.
27.
DiorioD, WelnerSA, ButterworthRF, MeaneyMJ, Suranyi-CadotteBE (1991) Peripheral benzodiazepine binding sites in Alzheimer’s disease frontal and temporal cortex. Neurobiol Aging12, 255–258.
28.
JanssenB, VugtsDJ, FunkeU, MolenaarGT, KruijerPS, van BerckelBN, LammertsmaAA, WindhorstAD (2016) Imaging of neuroinflammation in Alzheimer’s disease, multiple sclerosis and stroke: Recent developments in positron emission tomography. Biochim Biophys Acta1862, 425–441.
29.
YasunoF, OtaM, KosakaJ, ItoH, HiguchiM, DoronbekovTK, NozakiS, FujimuraY, KoedaM, AsadaT, SuharaT (2008) Increased binding of peripheral benzodiazepine receptor in Alzheimer’s disease measured by positron emission tomography with [11C]DAA1106. Biol Psychiatry64, 835–841.
30.
MaedaJ, ZhangMR, OkauchiT, JiB, OnoM, HattoriS, KumataK, IwataN, SaidoTC, TrojanowskiJQ, LeeVM, StaufenbielM, TomiyamaT, MoriH, FukumuraT, SuharaT, HiguchiM (2011) In vivo positron emission tomographic imaging of glial responses to amyloid-beta and tau pathologies in mouse models of Alzheimer’s disease and related disorders. J Neurosci31, 4720–4730.
31.
PaxinosG, FranklinKBJ (2004) The Mouse Brain in Stereotaxic Coordinates, 2nd edition. Gulf Professional Publishing.
32.
TaiYC, LaforestR (2005) Instrumentation aspects of animal PET. Annu Rev Biomed Eng7, 255–285.
33.
HashimotoH, KawamuraK, IgarashiN, TakeiM, FujishiroT, AiharaY, ShiomiS, MutoM, ItoT, FurutsukaK, YamasakiT, YuiJ, XieL, OnoM, HatoriA, NemotoK, SuharaT, HiguchiM, ZhangMR (2014) Radiosynthesis, photoisomerization, biodistribution, and metabolite analysis of 11C-PBB3 as a clinically useful PET probe for imaging of tau pathology. J Nucl Med55, 1532–1538.
34.
ZhangMR, KumataK, MaedaJ, YanamotoK, HatoriA, OkadaM, HiguchiM, ObayashiS, SuharaT, SuzukiK (2007) 11C-AC-5216: A novel PET ligand for peripheral benzodiazepine receptors in the primate brain. J Nucl Med48, 1853–1861.
35.
YangD, XieZ, StephensonD, MortonD, HicksCD, BrownTM, SriramR, O’NeillS, RaunigD, BocanT (2011) Volumetric MRI and MRS provide sensitive measures of Alzheimer’s disease neuropathology in inducible Tau transgenic mice (rTg4510). Neuroimage54, 2652–2658.
36.
MaedaJ, JiB, IrieT, TomiyamaT, MaruyamaM, OkauchiT, StaufenbielM, IwataN, OnoM, SaidoTC, SuzukiK, MoriH, HiguchiM, SuharaT (2007) Longitudinal, quantitative assessment of amyloid, neuroinflammation, and anti-amyloid treatment in a living mouse model of Alzheimer’s disease enabled by positron emission tomography. J Neurosci27, 10957–10968.
37.
BaileyRM, HowardJ, KnightJ, SaharaN, DicksonDW, LewisJ (2014) Effects of the C57BL/6 strain background on tauopathy progression in the rTg4510 mouse model. Mol Neurodegener9, 8.
38.
SpiresTL, OrneJD, SantaCruzK, PitstickR, CarlsonGA, AsheKH, HymanBT (2006) Region-specific dissociation of neuronal loss and neurofibrillary pathology in a mouse model of tauopathy. Am J Pathol168, 1598–1607.
39.
SaharaN, RenY, WardS, BinderLI, SuharaT, HiguchiM (2014) Tau oligomers as potential targets for early diagnosis of tauopathy. J Alzheimers Dis40(Suppl 1), S91–96.
40.
GroberE, DicksonD, SliwinskiMJ, BuschkeH, KatzM, CrystalH, LiptonRB (1999) Memory and mental status correlates of modified Braak staging. Neurobiol Aging20, 573–579.
41.
RileyKP, SnowdonDA, MarkesberyWR (2002) Alzheimer’s neurofibrillary pathology and the spectrum of cognitive function: Findings from the Nun Study. Ann Neurol51, 567–577.
42.
BarronM, GartlonJ, DawsonLA, AtkinsonPJ, PardonMC (2017) A state of delirium: Deciphering the effect of inflammation on tau pathology in Alzheimer’s disease. Exp Gerontol94, 103–107.
43.
HiguchiM, JiB, MaedaJ, SaharaN, SuharaT (2016) In vivo imaging of neuroinflammation in Alzheimer’s disease. Clin Exp Neuroimmunol7, 139–144.
44.
SyM, KitazawaM, MedeirosR, WhitmanL, ChengD, LaneTE, LaferlaFM (2011) Inflammation induced by infection potentiates tau pathological features in transgenic mice. Am J Pathol178, 2811–2822.
45.
GhoshS, WuMD, ShaftelSS, KyrkanidesS, LaFerlaFM, OlschowkaJA, O’BanionMK (2013) Sustained interleukin-1beta overexpression exacerbates tau pathology despite reduced amyloid burden in an Alzheimer’s mouse model. J Neurosci33, 5053–5064.
in t’ VeldBA, RuitenbergA, HofmanA, LaunerLJ, van DuijnCM, StijnenT, BretelerMM, StrickerBH (2001) Nonsteroidal antiinflammatory drugs and the risk of Alzheimer’s disease. N Engl J Med345, 1515–1521.
48.
BruggB, DubreuilYL, HuberG, WollmanEE, Delhaye-BouchaudN, MarianiJ (1995) Inflammatory processes induce beta-amyloid precursor protein changes in mouse brain. Proc Natl Acad Sci U S A92, 3032–3035.
49.
FialaM, CribbsDH, RosenthalM, BernardG (2007) Phagocytosis of amyloid-beta and inflammation: Two faces of innate immunity in Alzheimer’s disease. J Alzheimers Dis11, 457–463.
WischikCM, EdwardsPC, LaiRY, RothM, HarringtonCR (1996) Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines. Proc Natl Acad Sci U S A93, 11213–11218.
52.
BolognesiB, KumitaJR, BarrosTP, EsbjornerEK, LuheshiLM, CrowtherDC, WilsonMR, DobsonCM, FavrinG, YerburyJJ (2010) ANS binding reveals common features of cytotoxic amyloid species. ACS Chem Biol5, 735–740.
53.
SmithNW, AlonsoA, BrownCM, DzyubaSV (2010) Triazole-containing BODIPY dyes as novel fluorescent probes for soluble oligomers of amyloid Abeta1-42 peptide. Biochem Biophys Res Commun391, 1455–1458.
54.
JamesonLP, DzyubaSV (2013) Aza-BODIPY: Improved synthesis and interaction with soluble Abeta1-42 oligomers. Bioorg Med Chem Lett23, 1732–1735.
55.
TeohCL, SuD, SahuS, YunSW, DrummondE, PrelliF, LimS, ChoS, HamS, WisniewskiT, ChangYT (2015) Chemical fluorescent probe for detection of Abeta oligomers. J Am Chem Soc137, 13503–13509.
